CNC · Q2 2026 Earnings

Bullish

Centene Corporation

Reported July 28, 2026

30-second summary

Centene delivered Q2 FY2026 adjusted EPS of $2.51 versus consensus of $1.08 (+132% surprise) on revenue of $53.58B (+10% YoY, beating $47.45B by 12.9%), and raised the FY2026 adjusted EPS floor by $1.40 to greater than $4.80 alongside a $6B total revenue guide raise. Q2 consolidated HBR of 89.6% brought H1 to an 88.4% average, tracking well below the FY guide midpoint of 90.9% and consistent with a typical H2 seasonal step-up, while Medicaid at 93.9% is described by the company as "in-line with expectations." Management flagged approximately $0.50 of non-recurring items in Medicare and Commercial embedded in the raise, meaning the underlying run-rate lift is closer to $0.90 — still a decisive validation of the recovery thesis but with an explicit fence around what is structural.

Headline numbers

EPS

Q2 FY2026

$2.51

Revenue

Q2 FY2026

$53.58B

+10.0% YoY

+12.9% vs est.

Operating margin

Q2 FY2026

2.2%

Key financials

Q2 FY2026

Metric	Q2 FY2026	YoY	Q1 FY2026	QoQ
Revenue	$53.58B	+10.0%	$49.94B	+7.3%
EPS	$2.51	—	$3.37	-25.5%
Operating margin	2.2%	—	3.7%	-153bps

Guidance

Strong operational momentum drives significant upward revisions: FY2026 total revenue raised $6B, adjusted EPS raised $1.40 to >$4.80, and HBR improved, with ~$0.50 of non-recurring items in Medicare and Commercial segments.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

Metric	Period	Guide	YoY
Adjusted SG&A expense ratio	FY 2026	6.9% to 7.5%	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Total revenues	FY 2026	$187.5 billion to $191.5 billion	$193.5 billion to $197.5 billion	+$6.0 billion range midpoint increase (173.0 → 195.5)	Raised
Premium and service revenues	FY 2026	$171.0 billion to $175.0 billion	$173.0 billion to $177.0 billion	+$2.0 billion range increase	Raised
GAAP diluted EPS	FY 2026	> $2.37	> $3.11	+$0.74	Raised
Adjusted diluted EPS (non-GAAP)	FY 2026	> $3.40	> $4.80	+$1.40	Raised
Health Benefits Ratio (HBR)	FY 2026	90.9% to 91.7%	90.5% to 91.3%	-0.40 to -0.40 percentage points (range midpoint: 91.3% → 90.9%)	Lowered
SG&A expense ratio	FY 2026	7.0% to 7.6%	7.2% to 7.8%	+0.20 to +0.20 percentage points (range midpoint: 7.3% → 7.5%)	Raised
Investment and other income	FY 2026	$1.45 billion	Withdrawn — no replacement	—	Withdrawn

Segment KPIs

Q2 FY2026

Segment	Q2 FY2026	YoY
Medicaid	$22.766B	+5.0%
Commercial	$9.356B	-7.0%
Medicare	$11.057B	+17.0%

Other KPIs

Q2 FY2026

Segment	Q2 FY2026
Health Benefits Ratio (HBR)	89.6%
Medicaid HBR	93.9%
Commercial HBR	79.2%
Medicare HBR	89.5%
SG&A Expense Ratio	7.0%
Total at-risk membership	25.89 million
Days in Claims Payable	47 days
Operating Cash Flow	$3.6 billion

Management tone

Tone assessment based on press release language only; no earnings call transcript available for this quarter.

The press release pivots decisively to "underlying strength of the business" as the driver of the $6B revenue raise, and — critically — separates approximately $0.50 of non-recurring items in Medicare and Commercial from the structural lift. That itemization is the tell: management is willing to publicly parse what is durable versus what is transient rather than absorb both into a single number. CEO Sarah London framed the print as "meaningful milestones on our path to restoring profitability and increasing shareholder value." The Medicaid segment is described as "in-line with expectations," Commercial as "demonstrating significant year-over-year improvement in profitability," and Medicare as showing "fundamental outperformance in both Medicare Advantage and PDP."

The SG&A guide raise is the one line that undercuts an otherwise clean print. Q2 printed 7.0% — below the low end of the new 7.2–7.8% FY range — yet management chose to raise the FY midpoint by 20bps. The read is either undisclosed H2 investment spend or a deliberately conservative offset against the aggressive revenue raise.

What to watch into next quarter

Whether the FY HBR guide gets cut further alongside Q3 results — H1 consolidated HBR averaged 88.4% against the new 90.5–91.3% FY range, implying H2 needs to run near 92–93% to hit the midpoint. If Q3 prints below 91%, another 30–50bps cut becomes the base case

Whether SG&A actually steps up in H2 as the raised guide implies — Q2 at 7.0% versus new 7.2–7.8% FY range means H2 needs to run ~7.5%+. If Q3 SG&A stays near 7.0%, the guide raise reads as pure conservatism and the underlying EPS run-rate is higher than >$4.80 suggests

Durability of Medicaid HBR trend at seasonal peak — Q3 is typically the highest HBR quarter; watch whether the 93.9% Q2 print holds relative to a seasonal step-up

Sizing of the non-recurring Medicare/Commercial items — management flagged ~$0.50 of non-recurring benefit in the raise; a more granular breakdown would clarify the run-rate EPS power

Buyback cadence and share count — FY2026 diluted shares outstanding guide is 497.0–500.0M; watch whether Q3 tightens or moves the range as capital deployment discipline is tested by improving cash generation

Sources

Centene Q2 FY2026 press release, July 28, 2026 (SEC filing)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.